Arvinas (ARVN) vs Capricor Therapeutics (CAPR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Capricor Therapeutics (CAPR) has outperformed Arvinas (ARVN) over the past year, gaining 8.0% versus a loss of 19.9%. Over five years, CAPR leads with a +104.5% price change compared with -91.2% for ARVN. Arvinas is the larger company by market cap ($485.2 million vs $466.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARVN | CAPR |
|---|---|---|
| Share price | $7.52 | $8.02 |
| Market cap | $485.20M | $466.36M |
| 1-day change | +0.94% | -0.97% |
| YTD return | -37.18% | -71.93% |
| 1-year return | -19.89% | +8.00% |
| 5-year return | -91.25% | +104.55% |
| P/E ratio (TTM) | 28.92 | — |
| EPS (TTM) | $0.26 | $-2.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.51 | $40.37 |
| 52-week low | $6.97 | $2.96 |
| Distance from 52-week high | -48.17% | -80.13% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +85.24% | +236.60% |
| Average volume | 779.46K | 6.85M |
| Shares outstanding | 64.52M | 58.14M |
| Employees | 246 | 231 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CAPR has outperformed ARVN by 27.9 percentage points over the past year.
About Arvinas
ARVN stock →Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.
Health Care · Biotechnology: Pharmaceutical Preparations · 246 employees
About Capricor Therapeutics
CAPR stock →Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD.
Health Care · Biotechnology: Pharmaceutical Preparations · 231 employees
ARVN vs CAPR FAQ
Which is bigger, Arvinas or Capricor Therapeutics?
Arvinas (ARVN) is larger, with a market capitalization of $485.20M compared with $466.36M for Capricor Therapeutics (CAPR).
Which stock has performed better over the past year, ARVN or CAPR?
CAPR returned +8.00% over the past 12 months, compared with -19.89% for ARVN (price return, excluding dividends). Past performance does not predict future results.
Are Arvinas and Capricor Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.